|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang K, Johnson A, Ali SM, Klempner SJ,
Bekaii-Saab T, Vacirca JL, Khaira D, Yelensky R, Chmielecki J,
Elvin JA, et al: Comprehensive genomic profiling of advanced
esophageal squamous cell carcinomas and esophageal adenocarcinomas
reveals similarities and differences. Oncologist. 20:1132–1139.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liu B, Bo Y, Wang K, Liu Y, Tang X, Zhao
Y, Zhao E and Yuan L: Concurrent neoadjuvant chemoradiotherapy
could improve survival outcomes for patients with esophageal
cancer: A meta-analysis based on random clinical trials.
Oncotarget. 8:20410–20417. 2017.PubMed/NCBI
|
|
4
|
Bayat Mokhtari R, Homayouni TS, Baluch N,
Morgatskaya E, Kumar S, Das B and Yeger H: Combination therapy in
combating cancer. Oncotarget. 8:38022–38043. 2017.PubMed/NCBI
|
|
5
|
Yang X, Huang WT, Wu HY, He RQ, Ma J, Liu
AG and Chen G: Novel drug candidate for the treatment of several
softtissue sarcoma histologic subtypes: A computational method
using survivalassociated gene signatures for drug repurposing.
Oncol Rep. 41:2241–2253. 2019.PubMed/NCBI
|
|
6
|
Sun W, Sanderson PE and Zheng W: Drug
combination therapy increases successful drug repositioning. Drug
Discov Today. 21:1189–1195. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pan JX, Ding K and Wang CY: Niclosamide,
an old antihelminthic agent, demonstrates antitumor activity by
blocking multiple signaling pathways of cancer stem cells. Chin J
Cancer. 31:178–184. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Satoh K, Zhang L, Zhang Y, Chelluri R,
Boufraqech M, Nilubol N, Patel D, Shen M and Kebebew E:
Identification of niclosamide as a novel anticancer agent for
adrenocortical carcinoma. Clin Cancer Res. 22:3458–3466. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lu L, Dong J, Wang L, Xia Q, Zhang D, Kim
H, Yin T, Fan S and Shen Q: Activation of STAT3 and Bcl-2 and
reduction of reactive oxygen species (ROS) promote radioresistance
in breast cancer and overcome of radioresistance with niclosamide.
Oncogene. 37:5292–5304. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ye T, Xiong Y, Yan Y, Xia Y, Song X, Liu
L, Li D, Wang N, Zhang L, Zhu Y, et al: The anthelmintic drug
niclosamide induces apoptosis, impairs metastasis and reduces
immunosuppressive cells in breast cancer model. PLoS One.
9:e858872014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang YC, Chao TK, Chang CC, Yo YT, Yu MH
and Lai HC: Drug screening identifies niclosamide as an inhibitor
of breast cancer stem-like cells. PLoS One. 8:e745382013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Suliman MA, Zhang Z, Na H, Ribeiro AL,
Zhang Y, Niang B, Hamid AS, Zhang H, Xu L and Zuo Y: Niclosamide
inhibits colon cancer progression through downregulation of the
Notch pathway and upregulation of the tumor suppressor miR-200
family. Int J Mol Med. 38:776–784. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang J, Ren XR, Piao H, Zhao S, Osada T,
Premont RT, Mook RA Jr, Morse MA, Lyerly HK and Chen W:
Niclosamide-induced Wnt signaling inhibition in colorectal cancer
is mediated by autophagy. Biochem J. 476:535–546. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen L, Wang L, Shen H, Lin H and Li D:
Anthelminthic drug niclosamide sensitizes the responsiveness of
cervical cancer cells to paclitaxel via oxidative stress-mediated
mTOR inhibition. Biochem Biophys Res Commun. 484:416–421. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cheng B, Morales LD, Zhang Y, Mito S and
Tsin A: Niclosamide induces protein ubiquitination and inhibits
multiple pro-survival signaling pathways in the human glioblastoma
U-87 MG cell line. PLoS One. 12:e01843242017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang C, Zhou X, Xu H, Shi X, Zhao J, Yang
M, Zhang L, Jin X, Hu Y, Li X, et al: Niclosamide inhibits cell
growth and enhances drug sensitivity of hepatocellular carcinoma
cells via STAT3 signaling pathway. J Cancer. 9:4150–4155. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tomizawa M, Shinozaki F, Motoyoshi Y,
Sugiyama T, Yamamoto S, Sueishi M and Yoshida T: Niclosamide
suppresses Hepatoma cell proliferation via the Wnt pathway. Onco
Targets Ther. 6:1685–1693. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Han Z, Li Q, Wang Y, Wang L, Li X, Ge N,
Wang Y and Guo C: Niclosamide induces cell cycle arrest in G1 phase
in head and neck squamous cell carcinoma through Let-7d/CDC34 axis.
Front Pharmacol. 9:15442019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li R, You S, Hu Z, Chen ZG, Sica GL, Khuri
FR, Curran WJ, Shin DM and Deng X: Inhibition of STAT3 by
niclosamide synergizes with erlotinib against head and neck cancer.
PLoS One. 8:e746702013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim MO, Choe MH, Yoon YN, Ahn J, Yoo M,
Jung KY, An S, Hwang SG, Oh JS and Kim JS: Antihelminthic drug
niclosamide inhibits CIP2A and reactivates tumor suppressor protein
phosphatase 2A in non-small cell lung cancer cells. Biochem
Pharmacol. 144:78–89. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li R, Hu Z, Sun SY, Chen ZG, Owonikoko TK,
Sica GL, Ramalingam SS, Curran WJ, Khuri FR and Deng X: Niclosamide
overcomes acquired resistance to erlotinib through suppression of
STAT3 in non-small cell lung cancer. Mol Cancer Ther. 12:2200–2212.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu Z, Li Y, Lv C, Wang L and Song H:
Anthelmintic drug niclosamide enhances the sensitivity of chronic
myeloid leukemia cells to dasatinib through inhibiting
Erk/Mnk1/eIF4E pathway. Biochem Biophys Res Commun. 478:893–899.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jin Y, Lu Z, Ding K, Li J, Du X, Chen C,
Sun X, Wu Y, Zhou J and Pan J: Antineoplastic mechanisms of
niclosamide in acute myelogenous leukemia stem cells: Inactivation
of the NF-kappaB pathway and generation of reactive oxygen species.
Cancer Res. 70:2516–2527. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li J, Li H, Zhan D, Xiang M, Yang J, Zuo
Y, Yu Y, Zhou H, Jiang D, Luo H, et al: Niclosamide sensitizes
nasopharyngeal carcinoma to radiation by downregulating Ku70/80
expression. J Cancer. 9:736–744. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liao Z, Nan G, Yan Z, Zeng L, Deng Y, Ye
J, Zhang Z, Qiao M, Li R, Denduluri S, et al: The anthelmintic drug
niclosamide inhibits the proliferative activity of human
osteosarcoma cells by targeting multiple signal pathways. Curr
Cancer Drug Targets. 15:726–738. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li X, Ding R, Han Z, Ma Z and Wang Y:
Targeting of cell cycle and let-7a/STAT3 pathway by niclosamide
inhibits proliferation, migration and invasion in oral squamous
cell carcinoma cells. Biomed Pharmacother. 96:434–442. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li X, Yang Z, Han Z, Wen Y, Ma Z and Wang
Y: Niclosamide acts as a new inhibitor of vasculogenic mimicry in
oral cancer through upregulation of miR-124 and downregulation of
STAT3. Oncol Rep. 39:827–833. 2018.PubMed/NCBI
|
|
28
|
Arend RC, Londono-Joshi AI, Gangrade A,
Katre AA, Kurpad C, Li Y, Samant RS, Li PK, Landen CN, Yang ES, et
al: Niclosamide and its analogs are potent inhibitors of
Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.
Oncotarget. 7:86803–86815. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yo YT, Lin YW, Wang YC, Balch C, Huang RL,
Chan MW, Sytwu HK, Chen CK, Chang CC, Nephew KP, et al: Growth
inhibition of ovarian tumor-initiating cells by niclosamide. Mol
Cancer Ther. 11:1703–1712. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Arend RC, Londoño-Joshi AI, Samant RS, Li
Y, Conner M, Hidalgo B, Alvarez RD, Landen CN, Straughn JM and
Buchsbaum DJ: Inhibition of Wnt/β-catenin pathway by niclosamide: A
therapeutic target for ovarian cancer. Gynecol Oncol. 134:112–120.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu C, Lou W, Armstrong C, Zhu Y, Evans CP
and Gao AC: Niclosamide suppresses cell migration and invasion in
enzalutamide resistant prostate cancer cells via Stat3-AR axis
inhibition. Prostate. 75:1341–1353. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu C, Armstrong CM, Lou W, Lombard AP,
Cucchiara V, Gu X, Yang JC, Nadiminty N, Pan CX, Evans CP and Gao
AC: Niclosamide and bicalutamide combination treatment overcomes
enzalutamide- and bicalutamide-resistant prostate cancer. Mol
Cancer Ther. 16:1521–1530. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Schweizer MT, Haugk K, McKiernan JS,
Gulati R, Cheng HH, Maes JL, Dumpit RF, Nelson PS, Montgomery B,
McCune JS, et al: A phase I study of niclosamide in combination
with enzalutamide in men with castration-resistant prostate cancer.
PLoS One. 13:e01983892018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yu X, Liu F, Zeng L, He F, Zhang R, Yan S,
Zeng Z, Shu Y, Zhao C, Wu X, et al: Niclosamide exhibits potent
anticancer activity and synergizes with sorafenib in human renal
cell cancer cells. Cell Physiol Biochem. 47:957–971. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yu K, Wang T, Li Y, Wang C, Wang X, Zhang
M, Xie Y, Li S, An Z and Ye T: Niclosamide induces apoptosis
through mitochondrial intrinsic pathway and inhibits migration and
invasion in human thyroid cancer in vitro. Biomed Pharmacother.
92:403–411. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gartel AL and Tyner AL: The role of the
cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer
Ther. 1:639–649. 2002.PubMed/NCBI
|
|
37
|
Furtek SL, Matheson CJ, Backos DS and
Reigan P: Evaluation of quantitative assays for the identification
of direct signal transducer and activator of transcription 3
(STAT3) inhibitors. Oncotarget. 7:77998–78008. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yen CJ, Izzo JG, Lee DF, Guha S, Wei Y, Wu
TT, Chen CT, Kuo HP, Hsu JM, Sun HL, et al: Bile acid exposure
up-regulates tuberous sclerosis complex 1/mammalian target of
rapamycin pathway in Barrett's-associated esophageal
adenocarcinoma. Cancer Res. 68:2632–2640. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yang PW, Hung MC, Hsieh CY, Tung EC, Wang
YH, Tsai JC and Lee JM: The effects of Photofrin-mediated
photodynamic therapy on the modulation of EGFR in esophageal
squamous cell carcinoma cells. Lasers Med Sci. 28:605–614. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang C, Ma Q, Shi Y, Li X, Wang M, Wang
J, Ge J, Chen Z, Wang Z and Jiang H: A novel
5-fluorouracil-resistant human esophageal squamous cell carcinoma
cell line Eca-109/5-FU with significant drug resistance-related
characteristics. Oncol Rep. 37:2942–2954. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wu J, Wang L, Du X, Sun Q, Wang Y, Li M,
Zang W, Liu K and Zhao G: α-solanine enhances the chemosensitivity
of esophageal cancer cells by inducing microRNA-138 expression.
Oncol Rep. 39:1163–1172. 2018.PubMed/NCBI
|
|
43
|
Zhang X, Wu X, Zhang F, Mo S, Lu Y, Wei W,
Chen X, Lan L, Lu B and Liu Y: Paclitaxel induces apoptosis of
esophageal squamous cell carcinoma cells by downregulating STAT3
phosphorylation at Ser727. Oncol Rep. 37:2237–2244. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Andrews P, Thyssen J and Lorke D: The
biology and toxicology of molluscicides, bayluscide. Pharmacol
Ther. 19:245–295. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wieland A, Trageser D, Gogolok S, Reinartz
R, Höfer H, Keller M, Leinhaas A, Schelle R, Normann S, Klaas L, et
al: Anticancer effects of niclosamide in human glioblastoma. Clin
Cancer Res. 19:4124–4136. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Huang C, Wang L, Yang X, Lai L, Chen D and
Duan C: Expression of activated signal transducer and activator of
transcription-3 as a predictive and prognostic marker in advanced
esophageal squamous cell carcinoma. World J Surg Oncol. 13:3142015.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang Z, Zhu S, Shen M, Liu J, Wang M, Li
C, Wang Y, Deng A and Mei Q: STAT3 is involved in esophageal
carcinogenesis through regulation of Oct-1. Carcinogenesis.
34:678–688. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Timme S, Ihde S, Fichter CD, Waehle V,
Bogatyreva L, Atanasov K, Kohler I, Schöpflin A, Geddert H, Faller
G, et al: STAT3 expression, activity and functional consequences of
STAT3 inhibition in esophageal squamous cell carcinomas and
Barrett's adenocarcinomas. Oncogene. 33:3256–3266. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Yoshikawa T, Miyamoto M, Aoyama T, Soyama
H, Goto T, Hirata J, Suzuki A, Nagaoka I, Tsuda H, Furuya K and
Takano M: JAK2/STAT3 pathway as a therapeutic target in ovarian
cancers. Oncol Lett. 15:5772–5780. 2018.PubMed/NCBI
|
|
50
|
Yoon MK, Mitrea DM, Ou L and Kriwacki RW:
Cell cycle regulation by the intrinsically disordered proteins p21
and p27. Biochem Soc Trans. 40:981–988. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Xiang M, Chen Z, Yang D, Li H, Zuo Y, Li
J, Zhang W, Zhou H, Jiang D, Xu Z and Yu Z: Niclosamide enhances
the antitumor effects of radiation by inhibiting the
hypoxia-inducible factor-1α/vascular endothelial growth factor
signaling pathway in human lung cancer cells. Oncol Lett.
14:1933–1938. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zuo Y, Yang D, Yu Y, Xiang M, Li H, Yang
J, Li J, Jiang D, Zhou H, Xu Z and Yu Z: Niclosamide enhances the
cytotoxic effect of cisplatin in cisplatin-resistant human lung
cancer cells via suppression of lung resistance-related protein and
c-myc. Mol Med Rep. 17:3497–3502. 2018.PubMed/NCBI
|
|
53
|
Shi L, Zheng H, Hu W, Zhou B, Dai X, Zhang
Y, Liu Z, Wu X, Zhao C and Liang G: Niclosamide inhibition of STAT3
synergizes with erlotinib in human colon cancer. Onco Targets Ther.
10:1767–1776. 2017. View Article : Google Scholar : PubMed/NCBI
|
